These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21858897)

  • 1. Pitfalls in meta-analyses on adverse events reported from clinical trials.
    Huang HY; Andrews E; Jones J; Skovron ML; Tilson H
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1014-20. PubMed ID: 21858897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
    Manchikanti L; Datta S; Smith HS; Hirsch JA
    Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations.
    Hammad TA; Pinheiro SP; Neyarapally GA
    Clin Trials; 2011 Oct; 8(5):559-70. PubMed ID: 21878445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality.
    Cornelius VR; Perrio MJ; Shakir SA; Smith LA
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1223-31. PubMed ID: 19757414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment.
    Hammad TA; Neyarapally GA; Pinheiro SP; Iyasu S; Rochester G; Dal Pan G
    Clin Trials; 2013; 10(3):389-97. PubMed ID: 23508987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome.
    Ford AC; Guyatt GH; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2010 Feb; 105(2):280-8. PubMed ID: 19920807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting of adverse events in systematic reviews can be improved: survey results.
    Hopewell S; Wolfenden L; Clarke M
    J Clin Epidemiol; 2008 Jun; 61(6):597-602. PubMed ID: 18411039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.
    Hoaglin DC; Hawkins N; Jansen JP; Scott DA; Itzler R; Cappelleri JC; Boersma C; Thompson D; Larholt KM; Diaz M; Barrett A
    Value Health; 2011 Jun; 14(4):429-37. PubMed ID: 21669367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials.
    Papanikolaou PN; Ioannidis JP
    Am J Med; 2004 Oct; 117(8):582-9. PubMed ID: 15465507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some methodological points to consider when performing systematic reviews in comparative effectiveness research.
    Berlin JA; Cepeda MS
    Clin Trials; 2012 Feb; 9(1):27-34. PubMed ID: 22049086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data sources on drug safety evaluation: a review of recent published meta-analyses.
    Alves C; Batel-Marques F; Macedo AF
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):21-33. PubMed ID: 22025370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses.
    Paul M; Leibovici L
    Infect Dis Clin North Am; 2009 Jun; 23(2):277-93. PubMed ID: 19393909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the reporting and scientific quality of meta-analyses of randomized controlled trials of treatments for anxiety disorders.
    Bereza BG; Machado M; Einarson TR
    Ann Pharmacother; 2008 Oct; 42(10):1402-9. PubMed ID: 18728102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse drug reactions in hospitalized patients: A critique of a meta-analysis.
    Kvasz M; Allen IE; Gordon MJ; Ro EY; Estok R; Olkin I; Ross SD
    MedGenMed; 2000 Apr; 2(2):E3. PubMed ID: 11104449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the impact of attrition in randomized controlled trials.
    Hewitt CE; Kumaravel B; Dumville JC; Torgerson DJ;
    J Clin Epidemiol; 2010 Nov; 63(11):1264-70. PubMed ID: 20573482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team.
    Crowe BJ; Xia HA; Berlin JA; Watson DJ; Shi H; Lin SL; Kuebler J; Schriver RC; Santanello NC; Rochester G; Porter JB; Oster M; Mehrotra DV; Li Z; King EC; Harpur ES; Hall DB
    Clin Trials; 2009 Oct; 6(5):430-40. PubMed ID: 19846894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis and adverse drug reactions.
    Mittmann N; Liu BA; Knowles SR; Shear NH
    CMAJ; 1999 Apr; 160(7):987-8. PubMed ID: 10207335
    [No Abstract]   [Full Text] [Related]  

  • 19. Evidence-based practice: how to perform and use systematic reviews for clinical decision-making.
    Kranke P
    Eur J Anaesthesiol; 2010 Sep; 27(9):763-72. PubMed ID: 20523217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual patient meta-analysis of self-monitoring of an oral anticoagulation protocol.
    Perera R; Heneghan C; Fitzmaurice D;
    J Heart Valve Dis; 2008 Mar; 17(2):233-8. PubMed ID: 18512497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.